UNSPSC 51241117: Unoprostone

This classification denotes a prostaglandin analogue and anti-glaucoma agent with the molecular formula C22H38O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6X4F561V3W, chemically known as 13,14-dihydro-15-keto-20-ethyl pgf2alpha but generally known as unoprostone, which bears US NIH Compound Identifier 5311236. European Medicines Agency schedules Unoprostone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11381MIG.

UNSPSC 51241117 Unoprostone is a Commodity code that captures pharmaceutical supply agreements for state and local government health systems and facilities. The recent procurement activity under this code reflects broader generic pharmaceutical and OTC product sourcing through cooperative purchasing frameworks rather than procurement of the specific drug unoprostone in isolation. State and local buyers—health departments, correctional systems, mental health facilities, and other government-operated care settings—use this code to establish supply contracts with pharmaceutical manufacturers and authorized distributors. The work involves negotiating fixed or competitive pricing structures for multiple generic pharmaceuticals and OTC products, certifying compliance with cGMP and Drug Supply Chain Security Act requirements, maintaining EDI and chargeback system capabilities with authorized wholesalers, and providing comprehensive product data including NDC codes, SKUs, packaging configurations, and manufacturing locations. Vendors must carry substantial insurance coverage (commercial general liability of $5,000,000 per occurrence, network security liability of $2,000,000, and professional liability of $2,000,000) and agree to administrative fees, performance penalties, and contractual obligations spanning two years with optional renewals.

The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, posted the primary recent opportunity—a Request for Proposal for generic multi-source pharmaceuticals and OTC products with a response deadline of March 26, 2026. The contract targets participating state and local government facilities across multiple states including Oregon, with awarded vendors required to supply through three authorized wholesalers: AmerisourceBergen Drug Corporation (Cencora), Cardinal Health, and Morris & Dickson Co., LLC. Evaluation emphasizes price competitiveness (75 percent weighting), with the remainder distributed across fixed pricing, administrative compliance, EDI capability, and fee structure. All products must be available in the marketplace by May 15, 2026, with contract effectiveness set for July 1, 2026 and existing incumbent agreements extending through June 30, 2028.